Take Solutions Ltd. has informed that it has entered into an agreement with South Korea-based IL-Yang Pharma Company Ltd, for providing investigational new drug (IND) submission services to the company.     

The purpose of the IND submission is to gain USFDA (Food and Drug Administration) non-objection certification to study the investigational agent in humans.

According to an official release, the IND submission must include, sufficient preclinical data, including toxicity data; details of the chemistry, manufacturing and controls to provide adequate quality control information for the production of the agent and to describe the mechanism of action of the agent; background and rationale for intended clinical use and proposed protocol for Phase I human use.

The shares of the company closed today at Rs 38, up 7% compared to its previous close.